279 related articles for article (PubMed ID: 25347738)
1. Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling.
Hu J; Muller KA; Furnari FB; Cavenee WK; VandenBerg SR; Gonias SL
Oncogene; 2015 Jul; 34(31):4078-88. PubMed ID: 25347738
[TBL] [Abstract][Full Text] [Related]
2. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
Hu J; Jo M; Cavenee WK; Furnari F; VandenBerg SR; Gonias SL
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15984-9. PubMed ID: 21896743
[TBL] [Abstract][Full Text] [Related]
3. Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.
Gilder AS; Jones KA; Hu J; Wang L; Chen CC; Carter BS; Gonias SL
J Biol Chem; 2015 Jun; 290(24):14798-809. PubMed ID: 25837250
[TBL] [Abstract][Full Text] [Related]
4. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
[TBL] [Abstract][Full Text] [Related]
5. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
Schulte A; Liffers K; Kathagen A; Riethdorf S; Zapf S; Merlo A; Kolbe K; Westphal M; Lamszus K
Neuro Oncol; 2013 Oct; 15(10):1289-301. PubMed ID: 23877316
[TBL] [Abstract][Full Text] [Related]
7. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.
Lu KV; Zhu S; Cvrljevic A; Huang TT; Sarkaria S; Ahkavan D; Dang J; Dinca EB; Plaisier SB; Oderberg I; Lee Y; Chen Z; Caldwell JS; Xie Y; Loo JA; Seligson D; Chakravari A; Lee FY; Weinmann R; Cloughesy TF; Nelson SF; Bergers G; Graeber T; Furnari FB; James CD; Cavenee WK; Johns TG; Mischel PS
Cancer Res; 2009 Sep; 69(17):6889-98. PubMed ID: 19690143
[TBL] [Abstract][Full Text] [Related]
8. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
Fenton TR; Nathanson D; Ponte de Albuquerque C; Kuga D; Iwanami A; Dang J; Yang H; Tanaka K; Oba-Shinjo SM; Uno M; Inda MM; Wykosky J; Bachoo RM; James CD; DePinho RA; Vandenberg SR; Zhou H; Marie SK; Mischel PS; Cavenee WK; Furnari FB
Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14164-9. PubMed ID: 22891331
[TBL] [Abstract][Full Text] [Related]
9. A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.
Wykosky J; Hu J; Gomez GG; Taylor T; Villa GR; Pizzo D; VandenBerg SR; Thorne AH; Chen CC; Mischel PS; Gonias SL; Cavenee WK; Furnari FB
Cancer Res; 2015 Jan; 75(2):394-404. PubMed ID: 25432173
[TBL] [Abstract][Full Text] [Related]
10. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
[TBL] [Abstract][Full Text] [Related]
11. Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor.
Raghu H; Gondi CS; Dinh DH; Gujrati M; Rao JS
Mol Cancer; 2011 Oct; 10():130. PubMed ID: 22004682
[TBL] [Abstract][Full Text] [Related]
12. EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.
Roos A; Dhruv HD; Peng S; Inge LJ; Tuncali S; Pineda M; Millard N; Mayo Z; Eschbacher JM; Loftus JC; Winkles JA; Tran NL
Mol Cancer Res; 2018 Jul; 16(7):1185-1195. PubMed ID: 29724813
[TBL] [Abstract][Full Text] [Related]
13. The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival in Neurospheres.
Gilder AS; Natali L; Van Dyk DM; Zalfa C; Banki MA; Pizzo DP; Wang H; Klemke RL; Mantuano E; Gonias SL
Sci Rep; 2018 Feb; 8(1):2982. PubMed ID: 29445239
[TBL] [Abstract][Full Text] [Related]
14. A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen.
Eastman BM; Jo M; Webb DL; Takimoto S; Gonias SL
Cell Signal; 2012 Sep; 24(9):1847-55. PubMed ID: 22617030
[TBL] [Abstract][Full Text] [Related]
15. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor-mediated regulation of urokinase plasminogen activator expression and glioblastoma invasion via C-SRC/MAPK/AP-1 signaling pathways.
Amos S; Redpath GT; Dipierro CG; Carpenter JE; Hussaini IM
J Neuropathol Exp Neurol; 2010 Jun; 69(6):582-92. PubMed ID: 20467333
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis.
Feng H; Hu B; Jarzynka MJ; Li Y; Keezer S; Johns TG; Tang CK; Hamilton RL; Vuori K; Nishikawa R; Sarkaria JN; Fenton T; Cheng T; Furnari FB; Cavenee WK; Cheng SY
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3018-23. PubMed ID: 22323579
[TBL] [Abstract][Full Text] [Related]
18. Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature.
Jones KA; Gilder AS; Lam MS; Du N; Banki MA; Merati A; Pizzo DP; VandenBerg SR; Gonias SL
Neuro Oncol; 2016 May; 18(5):667-78. PubMed ID: 26420897
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib selectively inhibits tumor cell migration in EGFR-amplified human glioblastoma.
Parker JJ; Dionne KR; Massarwa R; Klaassen M; Foreman NK; Niswander L; Canoll P; Kleinschmidt-Demasters BK; Waziri A
Neuro Oncol; 2013 Aug; 15(8):1048-57. PubMed ID: 23749785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]